Open Access2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Author(s) -
Pellegrino Musto,
Monika Engelhardt,
Jo Caers,
Niccolò Bolli,
Martin Kaiser,
Niels W.C.J. van de Donk,
Evangelos Terpos,
Annemiek Broijl,
Carlos Fernández de Larrea,
Hartmut Goldschmidt,
Roman Hájek,
Annette Juul Vangsted,
Elena Zamagni,
Sonja Zweegman,
Michèle Cavo,
Meletios A. Dimopoulos,
Hermann Einsele,
Heinz Ludwig,
Giovanni Barosi,
Mario Boccadoro,
María Victoria Mateos,
Pieter Sonneveld,
Jesús F. San Miguel
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.278519
Subject(s) - multiple myeloma , medicine , lenalidomide , monoclonal gammopathy of undetermined significance , clinical trial , oncology , monoclonal , immunology , antibody , monoclonal antibody
According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and